GlassScriptPhysician profile
Sabrina Daughtry
NPI 1396459251
$11,491.33
in general payments reported to CMS, 2019-2025
30 companies · $6,981 in 2025
The $6,981 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,537 · 2024: $2,973 · 2025: $6,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,574 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $900 · Consulting Fee: $700 · Travel and Lodging: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,573.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $900.00 |
| Consulting Fee | $700.00 |
| Travel and Lodging | $317.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,541.73 | 2024-2025 | Xifaxan, Trulance |
| Ipsen Biopharmaceuticals, INC | $1,981.50 | 2024-2025 | Iqirvo, Bylvay |
| Abbvie INC. | $1,467.33 | 2023-2025 | |
| Madrigal Pharmaceuticals | $788.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $570.23 | 2025 | Tremfya, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $546.78 | 2024-2025 | Livdelzi, Epclusa, Vemlidy |
| Lilly USA, LLC | $429.22 | 2023-2025 | Omvoh, Mounjaro |
| Ardelyx, INC. | $413.88 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $319.29 | 2024-2025 | Voquezna |
| Genzyme Corporation | $310.79 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $236.00 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $203.97 | 2024-2025 | Vowst |
| Exact Sciences Corporation | $193.11 | 2023-2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $186.08 | 2023-2024 | Linzess |
| Qol Medical, LLC | $141.75 | 2023-2025 | Sucraid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $127.59 | 2025 | Livmarli |
| Pfizer INC. | $127.28 | 2025 | |
| Antares Pharma, INC. | $123.62 | 2023 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $122.08 | 2024 | |
| Novo Nordisk INC | $117.99 | 2023 | |
| Nestle Healthcare Nutrition INC. | $112.81 | 2023 | |
| Idorsia Pharmaceuticals US INC | $108.01 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $101.65 | 2025 | Entyvio |
| Coloplast Corp | $77.01 | 2023 | Altis |
| Acella Pharmaceuticals, LLC | $38.81 | 2023 | NP Thyroid 60 |
| Baxter Healthcare | $27.22 | 2023 | Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $22.29 | 2023 | Otezla, Repatha |
| Revance Therapeutics, INC. | $21.24 | 2024 | Daxxify |
| Braintree Laboratories, INC. | $17.40 | 2023 | Sutab |
| Paratek Pharmaceuticals, INC. | $16.10 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Daughtry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.